AstraZeneca (AZN) on Solana

$96.17

+1.11% (24h)

Volume (7d)

$360

Tokenized Value

$16.0M

Trades (7d)

Unique Traders

Variants

AstraZeneca Price Chart

Showing AZNx (highest volume)

AstraZeneca Variants on Solana

Token	Issuer	Price	24h Change	24h Volume	Tokenized Value	Trades
AZNx AstraZeneca xStock	-	$96.17	+1.11%	$360	$16.0M	5	Trade AZNx

About AstraZeneca on Solana

AstraZeneca is available on Solana through 1 bridged or wrapped variants. The most actively traded variant is AZNx (AstraZeneca xStock).

Each variant represents the same underlying AstraZeneca asset but is issued by a different bridge or protocol. When choosing which to trade, consider liquidity, volume, and the trust level of the issuing bridge.

Popular AstraZeneca variants:

AZNx — AstraZeneca xStock ($16.0M tokenized value)

AZN

AstraZeneca news, features & analysis

Matched on exact asset name, explicit ticker mentions, or associated variant token mints.

European Commission Grants Enhertu First Tumor-Agnostic HER2 ADC Approval in EU

The European Commission approved AstraZeneca and Daiichi Sankyo's Enhertu as a monotherapy for previously treated HER2-positive solid tumors, making it the first tumor-agnostic HER2-targeted antibody-drug conjugate authorized in the EU. The decision — Enhertu's sixth European indication — follows the EMA's Committee for Medicinal Products for Human Use recommendation in May 2026 and is supported by data from three phase II trials (DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02) showing clinically meaningful responses across a broad range of tumor types.

The approval triggers a $25 million milestone payment to AstraZeneca and Daiichi Sankyo and expands the drug's EU addressable patient population beyond its previously approved breast, gastric, and lung cancer indications. Enhertu had already achieved tumor-agnostic status in the United States and several other markets prior to this EU decision.
AstraZeneca Edges Higher as Broader Markets Slip

AstraZeneca (AZN) closed at $185.68, up 1.45% on the day, outpacing the S&P 500 which posted a marginal loss of 0.01% and the Nasdaq which fell 0.46%. The stock's relative strength appears supported by a modest valuation — AZN trades at a forward P/E of 19.48, a discount to the pharmaceutical industry average of 21.63, with a PEG ratio of 1.59 in line with peers.

Full-year consensus projects revenue of $63.18 billion for the year, representing 7.56% growth year-over-year, with EPS expected at $9.39 (+2.51% YoY). Near-term estimates are softer: next-quarter EPS is forecast at $2.10, down 3.67% from a year ago, and analyst consensus has been revised 8.41% lower over the past 30 days. AZN currently carries a Zacks Rank of #3 (Hold), suggesting the market views current pricing as fairly balanced against the mixed near-term earnings outlook.